APPLICANT

**MITRANI** 

DOCKET NO.

01/22858

SERIAL NO.

10/009,520

**FILED** 

June 22, 2000

**FOR** 

Methods of Inducing Angiogenesis .....

Receipt of the following papers is acknowledged by the U.S. Patent & Trademark Office as evidenced by the Mail Room Stamp:

RESPONSE TO MISSING REQUIREMENTS SEQUENCE LISTING AND FLOPPY DISC



Convensioner for Patents, Box PC1 United States Potent and Trademork Office Washington, D.C. 2023

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	_ATT	Y, DOCKET NO.
10/009,520	Eduardo Mitrani		01/22858
		INTERNATIONAL APPLICATION NO.	
	_	PCT/IL00/00365	
G E Ehrlich (1995) Ltd		I.A. FILING DATE	PRIORITY DATE
C/O Antonhy Castorina	_	06/22/2000	

G E Ehrlich (1995) Ltd C/O Antonhy Castorina 2001 Jefferson Davis Highway Suite 207 Arlington, VA 22202

CONFIRMATION NO. 4334 371 FORMALITIES LETTER

Date Mailed: 02/12/2002

## NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination
- Small Entity Statement


The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):



- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase Patentin Software, call (703) 306-2600
  - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

**DEBORAH D WILLIAMS** 

Telephone: (703) 305-3744

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/009,520	PCT/IL00/00365	01/22858

FORM PCT/DO/EO/905 (371 Formalities Notice)